Ready for Transfer

Pyrrolopyrimidine Compounds Designed to Stop the Spread of Tumors

RFT image

Laboratory: NIH’s National Center for Advancing Translational Sciences (NCATS)

Technology: Pyrrolopyrimidine compounds

Opportunity: These innovative compounds are available for licensing. NCATS is seeking partners interested in collaborative research to further develop, evaluate and commercialize this groundbreaking technology. 

Details: Pyrrolopyrimidine compounds are nontoxic and inhibit the formation and spreading of the perinucleolar compartment (PNC)—a sub-nuclear structure that typically runs rampant in metastatic tumors.

Benefits: Currently, there is no FDA-approved treatment for the clinical management of metastasis; however, these compounds would change that treatment practice. Aside from the obvious benefit of specifically targeting and halting the spread of metastatic tumors, these nontoxic compounds are broad-acting across all metastatic cancers.

Potential Applications:

  • Use in therapeutic intervention of metastasis in cancer
  • Use as a means to disrupt the PNC structure.

Contact: For more information on the pyrrolopyrimidine compounds, contact the NCATS Office of Strategic Alliances at NCATSPartnerships@mail.nih.gov.